Make your one-time, tribute, or recurring online gift to support brain tumour patient programs and research today: Donate
Dr. Sabine Mai
Manitoba Institute of Cell Biology, Winnipeg, MB
The proposed study focuses on ependymoma, a childhood brain tumour. At diagnosis, it is not possible to know which child will respond to treatment and which child will recur, i.e. if prognosis is favourable or non-favourable. We have developed quantitative tools that may allow for the distinction of good and poor responders at diagnosis.
These tools involve three-dimensional (3D) imaging of telomeres. Telomeres are the ends of chromosomes; they protect the chromosomes from damage and prevent recombination and fusion with other chromosomes (Mai, 2010). Telomere dysfunction therefore is associated with genomic instability and found in many cancers (Mai and Garini, 2006; Mai, 2010).
The data obtained in this study are quantitatively measured, and the output is expected to be a 3D nuclear telomeric profile of each child’s tumour, indicative of favourable or non-favourable disease and will, in the near future, enable for the first time a choice for specific treatments for each child’s ependymoma.
This June, 7-year-old Finley Kroeker will take part in the 2016 Winnipeg Brain Tumour Walk for his first time. Over the past two years, Finley has gone through more than what most people do their entire lives – and his brain tumour journey continues still.Learn more
Dave and I would often comment to each other how lucky we were to not have experienced any major life changing events in our lives. My...Learn more
Donna hopes she’s at a curve in the road. It’s been a long road since the diagnosis of a non-malignant brain tumour that has been...Learn more